Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7 Stomach Neoplasms 6 Colorectal Neoplasms 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 HER2-positive Gastric Cancer 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Muscle Invasive Bladder Carcinoma 1 Muscle Invasive Bladder Cancer (MIBC) 1 Muscle Invasive Bladder Cancer 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 HER2-low Breast Cancer 1 Gastric Adenocarcinoma 1 Endometrial Neoplasms 1 Castration-resistant Prostate Cancer 1 Biliary Tract Neoplasms 1

Interventions

apatinib 3 sintilimab 2 Taxes 2 Paclitaxel 2 Oxaliplatin 2 Hyperthermic Intraperitoneal Chemotherapy 2 Albumin-Bound Paclitaxel 2 trastuzumab deruxtecan 1 taxane 1 pembrolizumab 1 durvalumab 1 disitamab vedotin 1 cabozantinib 1 XELOX 1 Tegafur 1 Tadalafil 1 SHR-1701 1 S 1 (combination) 1 Platinum 1 Magnetic Resonance Spectroscopy 1 Injections 1 Gastrectomy 1 Drug Therapy 1 Drug Evaluation 1 Docetaxel 1 Cytoreduction Surgical Procedures 1 Cisplatin 1 Capecitabine 1 Bevacizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Gastric Adenocarcinoma × disitamab vedotin × Clear all

NCT07507526 2026-04-02

DTP-HER2

Sun Yat-sen University

Phase 2 Not yet recruiting

Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡